Regeneron's Trading Volume Surges 39.39% to $975 Million Ranking 74th in Market Activity

On May 2, 2025, Regeneron's trading volume reached $975 million, marking a 39.39% increase from the previous day, ranking 74th in the day's stock market activity. Regeneron Pharmaceuticals (REGN) rose by 2.65%.

Regeneron Pharmaceuticals, Inc. (REGN) has announced that the U.S. Food and Drug Administration (FDA) has approved its new drug application for Eylea (aflibercept) for the treatment of diabetic retinopathy. This approval is a significant milestone for the company, as it expands the indications for Eylea, which is already approved for the treatment of wet age-related macular degeneration and macular edema following retinal vein occlusion.

Regeneron's Eylea has shown promising results in clinical trials, demonstrating its efficacy in reducing the risk of vision loss in patients with diabetic retinopathy. The approval of Eylea for this new indication is expected to drive sales growth for the company, as diabetic retinopathy is a prevalent condition affecting millions of people worldwide.

In addition to the FDA approval, Regeneron has also announced that it has entered into a collaboration with a leading biotechnology company to develop a new class of cancer therapies. The collaboration will focus on the development of bispecific antibodies, which are designed to target multiple antigens on cancer cells, potentially improving the efficacy of cancer treatments.

Regeneron's collaboration with the biotechnology company is expected to accelerate the development of innovative cancer therapies, leveraging the company's expertise in antibody engineering and the biotechnology company's proprietary technology platform. The collaboration is a strategic move for Regeneron, as it expands its pipeline of oncology products and strengthens its position in the competitive cancer therapeutics market.